title: Combination therapy of an inhibitor of group VIA phospholipase A2 with paclitaxel is highly effective in blocking ovarian cancer development.
abstract: We and others have shown that calcium-independent phospholipase A(2) (iPLA(2)) is involved in epithelial ovarian cancer (EOC). Hence, we propose that iPLA(2) is a potential effective and novel target for EOC. We tested this concept and found that bromoenol lactone (BEL), a selective inhibitor of iPLA(2), significantly inhibited EOC metastatic tumor growth in mouse xenograft models using human SKOV3 and HEY ovarian cancer cells. Moreover, the combination of BEL with paclitaxel (PTX), one of the most commonly used therapeutic agents in EOC, almost completely blocked tumor development in the xenograft mouse model. BEL showed no detectable cytotoxic effects in mice. Another iPLA(2) inhibitor, FKGK11, also inhibited tumor development in the xenograft mouse model, supporting that the major target of action was iPLA(2). The additional effects of BEL with PTX in vivo likely stem from their distinct cellular effects. BEL and FKGK11 reduced adhesion, migration, and invasion of EOC cells in vitro; the reduced ability to adhere, migrate, and invade seems to increase the vulnerability of tumor cells to PTX. These results provide an important basis for the development of new treatment modalities for EOC.
authors.affiliation: Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
authors.forename: Hui
authors.initials: H
authors.lastname: Li
authors.forename: Zhenwen
authors.initials: Z
authors.lastname: Zhao
authors.forename: Caryl
authors.initials: C
authors.lastname: Antalis
authors.forename: Zhanzhong
authors.initials: Z
authors.lastname: Zhao
authors.forename: Robert
authors.initials: R
authors.lastname: Emerson
authors.forename: Gang
authors.initials: G
authors.lastname: Wei
authors.forename: Sheng
authors.initials: S
authors.lastname: Zhang
authors.forename: Zhong-Yin
authors.initials: ZY
authors.lastname: Zhang
authors.forename: Yan
authors.initials: Y
authors.lastname: Xu
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D002448:Cell Adhesion; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D005260:Female; D005466:Fluorocarbons; D054513:Group IV Phospholipases A2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007124:Immunoenzyme Techniques; D007659:Ketones / Q000627:therapeutic use; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D009281:Naphthalenes / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000201:enzymology / Q000473:pathology* / Q000517:prevention & control*; D017239:Paclitaxel / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011753:Pyrones / Q000627:therapeutic use*
chemical_list: C533806:1,1,1,2,2-pentafluoro-7-phenylheptan-3-one; D000972:Antineoplastic Agents, Phytogenic; D005466:Fluorocarbons; D007659:Ketones; D009281:Naphthalenes; D010726:Phosphodiesterase Inhibitors; D011753:Pyrones; C068314:6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one; D054513:Group IV Phospholipases A2; D017239:Paclitaxel